Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Fineline Cube Sep 7, 2026
Company PIC

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Fineline Cube Sep 7, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals

Eton Pharmaceuticals Licenses Auson’s Timolol Gel ASN001 for North America – Potential First Topical Therapy for Infantile Hemangioma in the U.S.

Fineline Cube Sep 8, 2026
Company Deals

China Medical System Licenses Leios Therapeutics’ Injectable Fat‑Reduction Therapy 10XB‑101 in Greater China, Alongside Strategic Equity Investment

Fineline Cube Sep 8, 2026
Company Deals

Samyang Holdings Partners with Yxintent for Lafullen Dermal Filler in China

Fineline Cube Jun 9, 2023

South Korea-based Samyang Holdings Biopharm Group has secured a partnership with Hangzhou-based Yxintent, a specialist...

Deals

Sequoia Capital to Split into Three Units, Including Independent China and India/SEA Divisions

Fineline Cube Jun 8, 2023

US-based investment fund Sequoia Capital has declared plans to reorganize its business into three distinct...

Company Drug

Jacobio Pharma Gets Green Light for Phase I/IIa Study of PARP7 Inhibitor JAB-26766

Fineline Cube Jun 8, 2023

China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to initiate a Phase...

Company

BioMarin Pharmaceutical to Discontinue Vimizim Import License in China

Fineline Cube Jun 8, 2023

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its decision not to renew the Import Drug...

Company Drug

Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS

Fineline Cube Jun 8, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...

Company Drug

Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023

Fineline Cube Jun 8, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...

Company Drug

Abbisko Therapeutics’ Pimicotinib Earns PRIME Status for TGCT from EMA

Fineline Cube Jun 8, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that its Category 1 drug...

Company Medical Device

NMPA Approves Shenzhen Core Medical’s Implantable Left Ventricular Assist System

Fineline Cube Jun 8, 2023

The National Medical Products Administration (NMPA) has issued market approval for the implantable left ventricular...

Company Deals

uBriGene Partners with Everlife Biomed to Advance iPSC Therapy Preparation

Fineline Cube Jun 8, 2023

China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO), has...

Company

EpimAb Biotherapeutics Appoints Dr. Zhu Yonghong as Chief Medical Officer

Fineline Cube Jun 8, 2023

Shanghai-based biotech company EpimAb Biotherapeutics has announced the appointment of Dr. Zhu Yonghong to the...

Company Drug

CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO

Fineline Cube Jun 7, 2023

CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...

Company Drug

BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial

Fineline Cube Jun 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...

Company Drug

Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL

Fineline Cube Jun 7, 2023

Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...

Company Drug

ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM

Fineline Cube Jun 7, 2023

Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...

Policy / Regulatory

China’s MOST Issues Updated HGR Rules Impacting Foreign Collaborations in Genetic Research

Fineline Cube Jun 7, 2023

China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...

Company Drug

Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA

Fineline Cube Jun 7, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...

Company Deals Digital

Shanghai Runda Medical Science and Technology Partners with Huawei Cloud on AI in Healthcare

Fineline Cube Jun 7, 2023

China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate...

Company Drug

Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia

Fineline Cube Jun 7, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Drug

Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma

Fineline Cube Jun 7, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...

Company Medical Device

Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge

Fineline Cube Jun 7, 2023

China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...

Posts pagination

1 … 568 569 570 … 717

Recent updates

  • Eton Pharmaceuticals Licenses Auson’s Timolol Gel ASN001 for North America – Potential First Topical Therapy for Infantile Hemangioma in the U.S.
  • China Medical System Licenses Leios Therapeutics’ Injectable Fat‑Reduction Therapy 10XB‑101 in Greater China, Alongside Strategic Equity Investment
  • China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation
  • Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018
  • HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eton Pharmaceuticals Licenses Auson’s Timolol Gel ASN001 for North America – Potential First Topical Therapy for Infantile Hemangioma in the U.S.

Company Deals

China Medical System Licenses Leios Therapeutics’ Injectable Fat‑Reduction Therapy 10XB‑101 in Greater China, Alongside Strategic Equity Investment

Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.